CoChat
Sign Up
Cited by 40Sarcoma Diagnosis and TreatmentBone Tumor Diagnosis and TreatmentsAcute Lymphoblastic Leukemia research

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

Treatment of Refractory Osteosarcoma With Fractionated Cyclophosphamide and Etoposide

Rodríguez-Galindo, Carlos, Daw, Najat C., Kaste, Sue C., Meyer, William H., Dome, Jeffrey S., Pappo, Alberto S., Rao, Bhaskar N., Pratt, Charles B.·2002·Journal of Pediatric Hematology/Oncology
DOI 10.1097/00043426-200205000-00006
Open this paper in CoChat — free account

Abstract

PURPOSE: Standard multiagent chemotherapy for osteosarcoma may include platinum compounds, doxorubicin, and high-dose methotrexate. By identifying new chemotherapeutic strategies, the outcome of these patients can be improved and the toxicity of treatment regimens decreased. PATIENTS AND METHODS: The authors evaluated the activity of the combination of cyclophosphamide (500 mg/m2 per day for 5 days) and etoposide (100 mg/m2 per day for 5 days) given with granulocyte colony-stimulating factor (G-CSF) to children with osteosarcoma unresponsive to conventional treatment. RESULTS: Fourteen patients with refractory osteosarcoma were treated with this combination. Twelve patients had been previously treated with a multiagent regimen that included carboplatin, ifosfamide, methotrexate, and doxorubicin. Seven of 11 evaluable patients had a poor histologic response in their primary tumor at the time of definitive surgery (Huvos grade 1 or 2). Sites of relapse included lung, bone, and brain. A total of 47 courses were given. An overall response rate of 28.5% was achieved. A complete response was obtained in one patient (7.1%), a partial response was obtained in three patients (21.4%), and stable disease for 1 to 4 months was achieved in five patients (35.7%). Five patients (35.7%) had progressive disease. Grade 4 neutropenia was the primary form of toxicity observed; the median duration of absolute neurophil count less than 500/microL was 4 days. CONCLUSIONS: The combination of cyclophosphamide and etoposide resulted in a response rate of 28.5% in patients with refractory or relapsed osteosarcoma, and its incorporation into front-line therapies deserves further evaluation.

Overview

Integrity signals

Registry

Crossref · 10.1097/00043426-200205000-00006

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 11

  1. Lilley, 1990, Cancer Res, 50, 284
  2. Teicher, 1989, Cancer Res, 49, 5994
  3. Meyer, 1994, Proceedings of the Annual Meeting of the American Association for Cancer Research, 35, 241
  4. Marti, 1985, Cancer Treat Rep, 69, 115
  5. Pratt, 1987, Cancer Treat Rep, 71, 131
  6. Sladek, 1984, Cancer Treat Rep, 68, 1247
  7. Boddy, 1993, Cancer Res, 53, 3758
  8. Ren, 1997, Cancer Res, 57, 4229
  9. Dombernofski, 1973, Acta Pathol Microbiol Scand, 81, 715
  10. Chang, 1985, Cancer Res, 45, 2434
  11. Kung, 1985, Proceedings of the Annual Meeting of the American Society of Clinical Oncology, 4, 235

Cited by

Sorted by citations

See all 40

Related

See all

Metadata

Authors
Rodríguez-Galindo, C., Daw, N. C., Kaste, S. C., Meyer, W. H., Dome, J. S., Pappo, A. S., Rao, B. N., & Pratt, C. B.
Affiliations
St. Jude Children's Research Hospital (US)
ORCID
Venue
Journal of Pediatric Hematology/Oncology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2002-05
Volume
24
Issue
4
Pages
250-255
ISSN
1077-4114 (ISSN-L)
DOI
10.1097/00043426-200205000-00006
OpenAlex
W2073867312
Cited by
40
References
52
Citations by year
2026: 2 · 2024: 2 · 2023: 1 · 2022: 3 · 2020: 2 · 2019: 2 · 2018: 2 · 2016: 1 · 2015: 2 · 2014: 4 · 2012: 3
FWCI
2.48
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Pediatric Hematology/Oncology (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Cancer Institute (CA-23099, P01CA023099, P 30CA 21765, P30CA021765)
Topics
  • Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
  • Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
Keywords
relapsed osteosarcoma, cyclophosphamide, etoposide, fractionated chemotherapy, granulocyte colony-stimulating factor, pediatric osteosarcoma, neutropenia, treatment toxicity, combination chemotherapy
MeSH terms
Adolescent, Antineoplastic Combined Chemotherapy Protocols, Bone Neoplasms, Child, Cyclophosphamide, Dose-Response Relationship, Drug, Etoposide, Female, Humans, Male, Neoplasm Recurrence, Local, Retrospective Studies, Osteosarcoma, Survival Rate, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review